Brandon Medical’s light shines on

by Joel Lane 30. November 2009 17:29

Medtech company Brandon Medical has won two awards for innovation and business achievement at the National Chambers awards 2009.

At the ceremony, held at the National Maritime Museum, Greenwich, the Yorkshire company received £50,000 with the Outstanding Business Achievement award.

The Technology through Innovation award recognised Brandon's innovative HD-LED medical lighting and Symposia medical audio-visual systems.

John Dunsmure, Managing Director of the Chamber of Commerce, said:

"Brandon is a shining example of what a good British business can do in a global market. The company has used its intelligence and experience to develop a set of unique products that is helping the medical profession improve the way it shares vital information. That really could save lives."

The award ceremony was hosted by BBC news reporter Fiona Bruce and TV presenter Mark Durden Smith. A total of 10 award categories were covered, recognising the success of businesses across the UK.

Brandon Medical is a specialist medical lighting manufacturer. Its HD-LED light source, launched in 2008, aims to provide the best possible lighting during operations. The HD-LED is cheap to produce and highly energy-efficient, potentially reducing energy consumption by half, as well as being recyclable and easy to dispose of.

The Symposia medical audio-visual system, designed for live surgery and surgical training, has been installed throughout the UK. Sir Liam Donaldson, Chief Medical Officer, commented: "I am pleased to see surgical training enhanced by smart use of modern technology."

Graeme Hall, Brandon Medical's Managing Director, said: "Brandon Medical is dedicated to providing new innovations to improve hospitals and patient care. It's great to see our investments in research and development recognised in this way."

Brandon Medical is a family-owned company based in Leeds, with 30 employees across an office and manufacturing site.

Brandon 3

HD-LED Medical Lighting

Tags:

Medtech News

NICE supports Humira and Remicade for Crohn’s disease

by Admin 30. November 2009 16:44

NICE has recommended Remicade (infliximab) and Humira (adalimumab) as treatment options for some people with severe Crohn’s disease whose condition has not responded to conventional therapy.

The draft guidance recommends the drugs for adults with non-fistulising, severe Crohn’s disease that has not responded to conventional treatment.

The Institute also ruled that treatment should normally be started with the less expensive drug, taking into account drug administration costs, required dose and price per dose.

Infliximab was also recommended for adults with severe, fistulising Crohn’s disease, and for children and young people aged 6-17 years old with severe Crohn’s disease.

Dr Carole Longson, Health Technology Evaluation Centre Director, said: “These treatments are not suitable for all people with Crohn’s disease. However, it is clear that infliximab and adalimumab may provide benefit to some severely ill patients; hence our draft guidance is targeted at people who have the most severe forms of Crohn’s disease. It is also clear that these drugs should only be prescribed by specialists experienced in treating people with Crohn’s disease.”

Crohn’s disease is a chronic inflammatory condition of unknown cause affecting the gastrointestinal tract (gut). It is estimated that around 60,000 people in the UK have the disease, of whom approximately 3,000 (5%) have the most severe forms of the condition.

Sometimes Crohn’s disease causes the formation of abnormal passageways (‘fistulas’) between parts of the intestine or between the intestine and the skin. It can also affect other parts of the body, such as the eyes or the joints. People with Crohn’s disease have recurrent attacks, i.e. periods of flares and ‘remission’.

The draft guidance is available for public consultation on the NICE website until 10 December 2009 and final guidance is expected in spring 2010. Until this time, NHS bodies have been encouraged to make local funding decisions on the treatments.

Tags:

News

EC approves anti-arrhythmic drug

by Admin 30. November 2009 16:34

Sanofi-aventis’ Multaq has become the first new anti-arrhythmic drug to be approved in the European Union in the last 10 years.

The European Commission has granted marketing authorisation for Multaq (dronedarone – 400mg Tablets) in all 27 European member states. The approval follows the CHMP’s positive opinion issued on September 25, 2009.

The drug is indicated in adult clinically stable patients with a history of, or current non-permanent atrial fibrillation (AF) to prevent recurrence of AF or to lower ventricular rate.

It is the first anti-arrhythmic drug approved in the EU that has shown a clinical benefit to reduce cardiovascular hospitalisations or death from any cause in patients with AF/AFL.

“The approval of Multaq in the European Union is important news for atrial fibrillation patients who will now have access to a new treatment approach,” said Marc Cluzel, Executive Vice President, Research and Development, sanofi-aventis. “The approval of Multaq is the result of more than 15 years of research and development conducted by sanofi-aventis and supported by the commitment of the experts involved in the clinical development program and AF patients participating in the trials.”

The marketing authorisation was based on a clinical data package that included seven international clinical trials involving more than 7000 patients, with almost 4000 patients receiving dronedarone during the program.

“This European approval is good news for doctors and patients since atrial fibrillation affects about 4.5 million people in Europe and represents one-third of hospitalisations for arrhythmia in the European Union,” said Dr Stefan H. Hohnloser, Goethe University's Division of Clinical Electrophysiology, Frankfurt, Germany.

He added: “Multaq is a significant step forward which could change the way we approach the management of atrial fibrillation and offers a new treatment option to physicians in a field where there has been no significant anti-arrhythmic drug innovation for almost 20 years.”

The first launches of Multaq are expected to take place in the United Kingdom and Germany in January 2010.

Tags:

News

Effective team meetings (part 2)

by Admin 29. November 2009 08:47

meeting Instead of being a motivational boost to your team, most sales team meetings are boring and too information-driven. Based on his work with sales teams around the world, Andy Preston gives his tips and techniques for successful meetings.  

Whenever I’m talking to or working with sales managers, they invariably ask me for some help in running the team sales meetings. They realise that running a compelling sales meeting is vitally important, but aren’t always sure of the best way to go about it. Generally speaking, there are two types of sales meeting, the quick ‘gee up’, lasting no more than 30 minutes, or the monthly, all-day affair more common to field sales teams. The all-day monthly meeting is much more difficult to organise and deal with, and that’s what I’m going to focus on in this article, although most of the tips would apply to weekly or daily sales meetings as well.  

Tip 1 – The meeting doesn’t have to last the whole day This is a really important point. As a salesperson, I’ve lost count of the number of sales meetings I’ve sat through, thoroughly bored, as the person leading the meeting is obviously ‘spinning out’ the content and topics to fill time. This is pointless. Why not plan other activities for the afternoon – something that will help inspire and motivate the team?

Tip 2 – Plan and prepare for the meeting Most sales meetings are only thought about when they’re about to happen. Think well in advance what you want to cover in the meeting. Of course, it’s only sensible to leave room for last minute things you want to add, but planning the majority of the meeting well in advance can result in far more productive meetings. Sending out an agenda in advance of the meeting would also mean the team has some idea of what is going to be covered and they can prepare if necessary. However, it can also be a good thing to keep some things as a surprise to help keep the team on their toes. Give some thought to your objectives for the meeting and what you want to happen afterwards. Make sure at each stage that the meeting is progressing towards the outcomes you have set and not falling into meaningless discussions or chit-chat.

Tip 3 – Think carefully before discussing product literature Another ‘habit’ of sales managers is to give out product literature at meetings, go through it in detail and then ask for their salespeople’s thoughts on it. This is a big mistake. Make sure you send out any literature beforehand, so the salespeople have had chance to review it before the meeting, then you’ll get more relevant feedback and questions because they’ve had chance to study it.  

Tip 4 - Challenge their pipeline This should be one of the most important parts of any sales meeting, yet most sales managers handle it badly. As well as looking at how the salesperson has performed over the last month (and how they’re performing currently), the sales manager should also be looking at any potential customers they have in the pipeline. I still remember working with a media company where the first time I met with the team was when I was running their sales meeting. I asked a particular salesperson to talk about their pipeline and likely customers for the next month. He mentioned two with no problems, but when he mentioned the name of the third, laughter filled the room as if a joke had been told. When I challenged the salesperson, it turned out the reason everyone was laughing is that that potential customer had been on his list since he started with the company nearly a year ago. What I find more incredible is that the sales manager had never challenged him on it.

Tip 5 - Share best (and worst) practice Wouldn’t it make sense that if one member of your team is having great success doing something, that the rest of your team should be doing it as well? Or if something really didn’t help them, then the rest of the team should also be avoiding it? This is something that sales teams often fail to do. Whether it’s because salespeople don’t want to help their in-house ‘competition’ or whether it’s through plain apathy, it should happen far more often than it does. If you’ve got something that’s working better than everything else, every member of the team should be using it! Whether it’s something a salesperson has found out about the market, a rival product or company or just a new idea, get it shared amongst the team and let everyone take advantage of it. The more you can instil a sense of trust and sharing of best practice within your team, the better it is for all concerned.

Tip 6 - Make it motivational This is probably one of the most important (but most forgotten about) areas. Every time your sales team gets together, it’s either an opportunity to motivate them, or an opportunity to de-motivate them. Most sales managers miss the opportunity to motivate or re-motivate their team, and if this happens regularly then the result is the team actually get de-motivated because of it. The danger is that they will start to view the sales meeting as an inconvenience and something to ‘get through’, rather than something that is useful and can help them achieve their targets. The key here is to ensure that before the team leave, you’ve motivated them as much as possible to go out and smash their sales targets for the month. This becomes especially important if you only get the team together once a month, so make sure you take advantage of the opportunity.  

Got a question about this article, or want some specific ideas on running your team’s sales meetings? Drop me a line with any questions at www.andy-preston.com/ask-andy/. Andy Preston is a leading authority on sales and sales management. You can see and hear more about Andy at www.andy-preston.com.

Tags:

Features

Innovation Pass for drugs for rare diseases

by Admin 28. November 2009 16:41

A pilot to help patients get innovative new drugs not currently available on the NHS has been launched for consultation by Health Minister Mike O’Brien and Science and Innovation Minister Lord Drayson.

During the three-year pilot, an ‘Innovation Pass’ will allow patients with rarer diseases access to innovative new drugs and enable valuable data to be collected on their impact and cost effectiveness, contributing towards a future NICE appraisal.

The Office for Life Sciences (OLS) Blueprint, published in July, detailed the Government’s commitment to create the ‘Innovation Pass’ to allow access to drugs for rare diseases that are not yet appraised by NICE, and where there is limited data on their effectiveness.

As the number of patients using these drugs is small, the lack of current evidence available means that NICE are not able to conduct a full assessment for their use on the NHS.

Health Minister Mike O’Brien said: “I am extremely pleased to launch this consultation that will help patients with the greatest need to benefit from and get access to exciting new innovative drugs. The Innovation Pass pilot will help collect the essential data needed to demonstrate that such drugs, which would not otherwise be available to patients, are making a big difference to their lives.”

The Innovation Pass pilot is being run in partnership with NICE and has involved significant input from a range of stakeholders including the NHS and the life sciences industries. In 2010/11 it will be funded from a £25m budget set aside exclusively for the Innovation Pass. Funding for future years is discussed in the consultation.

Drugs included on the scheme will be licensed and NICE is to play a key role in developing and applying the drug eligibility criteria for the Innovation Pass. All drugs included on the pilot will be submitted for NICE appraisal at the end of the three years.

NICE Chief Executive Andrew Dillon added: “We recognise that for a small number of very promising new treatments, the evidence available may not reveal their full potential benefits for patients. Where there is a high risk that a NICE appraisal of a new treatment at the point of its first use in the NHS might underestimate its benefits, providing the opportunity to gather more evidence and making the treatment available before undertaking an appraisal is the right thing to do.”

The Innovation Pass pilot consultation will run for 10 weeks, closing on 8th February 2010.

Tags:

News

Demand growing for treatments for drug resistant HIV strains, finds Frost & Sullivan

by Admin 28. November 2009 09:29

The HIV/AIDS market in Europe will exhibit strong growth due to the introduction of novel drug classes and increasing efforts to achieve high diagnosis rates, industry analysts Frost & Sullivan predict.

The market faces a number of hurdles in the form of late diagnosis and low awareness levels. However, new analysis from Frost & Sullivan, European HIV/AIDS Therapeutics Markets, finds that the markets earned revenues of $3.88 billion in 2008 and estimates this will reach $6.79 billion in 2015.

“Market growth will be spurred by the new drug classes and combination therapies introduced recently,” notes Sylvia M. Findlay, programme manager Pharmaceuticals & Biotechnology from Frost & Sullivan. “Novel drug classes which treat drug resistant HIV strains are expected to be used in combination with first-line therapy in experienced patients. Combination therapies which minimise side-effects and pill burden are supporting market development.”

A difficult market

New drug classes are being researched and introduced into the market, especially targeting experienced patients, Frost & Sullivan explains. These drugs are being tested in clinical trials for use in combination with established first-line therapies and also as first-line therapies themselves. Proving the long-term safety and efficacy of these drugs is anticipated to boost their uptake and revenues.

The analysts point out, however, that Europe is at a disadvantage because of the ban on direct-to-consumer marketing and because the launch and uptake of drugs is slower than in the US market. Social stigma and discrimination associated with HIV/AIDS, especially in Eastern Europe, is further limiting the growth potential of the market.

“Europe is a very diverse market where epidemiology, regulations and awareness levels vary considerably,” explains Miss Findlay. “The level of adherence to recommended therapy regimens varies across the region, largely due to the lack of awareness about the safety and efficacy profiles of drugs used.”

Moreover, she adds, diagnoses rates, which are influenced by awareness and societal pressures, vary across the region. This demands the formulation of region-specific strategies to promote market growth.

Call to action

Frost & Sullivan urges companies to update their knowledge of epidemiology, promote adherence to recommended therapies and enhance awareness on a continuous basis. Companies need to devise strategies to address challenges that impede the growth of their product portfolio, they argue. Market participants should use prescription trends to assess the market potential for their drugs, both as a first-line and a second-line therapy.

“Physicians are the sole point of contact for patients in Europe, given the absence of direct-to-consumer marketing,” says Miss Findlay. “Analysing prescription trends and patients’ perception towards new drugs as well as the drugs they are currently using is imperative to maintain patient base.”

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents.

Tags: ,

Features

UKTI supports medtech collaboration

by Joel Lane 27. November 2009 16:47

A new biotechnology venture supported by UKTI has seen a British and a Japanese company working together to develop handheld devices for point of care diagnosis of infectious diseases.

New company OJ-Bio is a joint venture between Orla Protein Technologies and Japan Radio Company (JRC) to develop and commercialise next-generation sensor technology in Newcastle.

The two companies have been supported by UKTI's R&D Globalisation Programme, which is designed to help R&D-based businesses protect and commercialise their IP and develop new products for international markets.

Delivered by innovation agency RTC North, the Programme initially helped both companies to structure a joint R&D programme to establish whether their combined technology could create a platform for fast and accurate detection of diseases.

The new technology, which combines JRC's mobile telecommunication devices and Orla's biological surfaces, has proven to be suitable for a range of portable handheld devices that can rapidly detect various infectious diseases. The devices can transmit test results through wireless networks, and so can be used anywhere - even in remote parts of the world.

Following the R&D collaboration, RTC North helped JRC and Orla to form a joint venture, OJ-Bio, which will be based at the Centre for Life in Newcastle.

Dale Athey, CEO of Orla, said: "The assistance provided by RTC North through UKTI's R&D Globalisation Programme has been invaluable to us, and will likely benefit many more SMEs like us in the region."

Ray Jones of RTC North said: "It's been a long process to get the technology to where it is today, but it represents a major step forward in the long-term fight in the detection of diseases."

3318200806

OJ-Bio launch

Tags:

Medtech News

EC approves Micardis for cardiovascular disease

by Admin 27. November 2009 16:43

Boehringer Ingelheim’s Micardis (telmisartan) has been approved by the European Commission to reduce the risk of cardiovascular (CV) morbidity in high CV risk patients.

The granting of a marketing authorisation for Micardis to reduce CV morbidity in patients with manifest atherothrombotic CV disease or type 2 diabetes with documented target organ damage follows recent FDA approval in the US.

The drug is the only treatment in its class that demonstrates proven cardiovascular (CV) protection in patients at high CV risk and that has been approved in this indication.

The new indication is based on a review of clinical trials, including results from the ONTARGET trial, which showed that Micardis may prevent one in five serious CV events.

Professor Giuseppe Mancia, Professor of Medicine and Chairman of the Department of Clinical Medicine of the University of Milan, Bicocca, Italy, said: “This new indication of telmisartan is a significant development for physicians and their at-risk patients. Prevention of CV events is vital as these are the primary causes of pathological death in Europe, due to lack of proper control of treatable risk factors and disease. The approval of telmisartan offers patients a well-tolerated treatment option which also provides CV protection.”

Professor Klaus Dugi, Corporate Vice President, Medical Affairs, Boehringer Ingelheim, commented: “These approvals clearly demonstrate the unique treatment option that Micardis now provides to both physicians and patients as the only medication in the ARB class to provide proven CV protection.”

Cardiovascular disease (CVD) is responsible for nearly one in three deaths worldwide and is the number one cause of death.

Tags:

News

Owen Mumford appoints two managers

by Joel Lane 27. November 2009 16:42

Oxfordshire medical device manufacturer Owen Mumford has appointed two new members to its management team.

Paul Currah has been appointed as Strategic Purchasing Manager in the Operations Division and Nancy Neilson as Site Quality Assurance Manager at the company's Chipping Norton site.

Reporting to Mark Owen, Operations Director, Paul Currah will be part of the senior management team and will lead the company's purchasing.

Paul joins Owen Mumford from GSK, where he was Sourcing Group Manager. He has 15 years' experience in procurement and supplier development, and held a key purchasing role at Abbott's Diabetes Care business.

Mark Owen said: "As we develop our global business plan, the role of strategic purchasing is one of the key areas of focus and we are confident Paul will play a vital role in our future success."

Reporting to David Farrier, Corporate Quality Assurance Manager, Nancy Neilson will oversee the management of the site's quality assurance system and quality assurance team.

Nancy joins Owen Mumford from GSK in Scotland, where she was Compliance Projects Manager and QMS Champion. Her role was to manage the implementation of the quality management system and ensure its success.

David Farrier said: "As a leading healthcare company, quality assurance is our top priority and therefore recruiting someone of Nancy's calibre and from such a pedigree background to oversee this area of our business is an excellent step forward."

Based in Woodstock, Owen Mumford manufactures medical devices for the treatment of diabetes and other conditions.

Paul&NancyOM

Paul Currah and Nancy Neilson

Tags:

Medtech News

Not so minimally invasive

by Joel Lane 26. November 2009 17:26

A private healthcare surgeon in the UK has been sued for compensation by a patient, Mr R. Bloch, who alleges that the surgeon accidentally removed his left testicle while conducting laparascopic surgery to remove a gall stone.

During the initial hearing, the judge asked whether any corroborating evidence was available. The patient's solicitor produced a small glass jar, placed it on the judge's bench and declared: "Your Honour, the ball is in your court."

Tags:

Medtech News

TextBox

Tag cloud

Calendar

<<  May 2013  >>
MoTuWeThFrSaSu
293012345
6789101112
13141516171819
20212223242526
272829303112
3456789

View posts in large calendar